VEF SAU Pharmaceutical Import Profile — Uzbekistan (DGFT 2022–2026)

Name: VEF SAU Pharmaceutical Import Records from India — 2 Products, $300.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

VEF SAU — Pharmaceutical Importer Profile (2026) | 2 Products, $300.0K Trade | TransData Nexus

VEF SAU

Pharmaceutical Importer · Uzbekistan · Advanced Oncology Focus · $300.0K Total Trade · DGFT Verified

VEF SAU is a pharmaceutical importer based in Uzbekistan with a total trade value of $300.0K across 2 products in 1 therapeutic categories. Based on 6 verified import shipments from Indian Customs (DGFT) records, VEF SAU is the #1 buyer in 1 product including Ifosfamide. VEF SAU sources from 1 verified Indian supplier, with Vivalia Remedies Private Limited accounting for 100.0% of imports.

VEF SAU — Import Portfolio & Supplier Network

VEF SAU import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to VEF SAU?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Vivalia Remedies Private Limited	$300.0K	6	100.0%

VEF SAU sources from 1 verified Indian supplier across 2 distinct formulations. The sourcing is highly concentrated — Vivalia Remedies Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does VEF SAU Import?

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bleomycin	Advanced Oncology	$150.0K	3	2.7%	3
2	Ifosfamide	Advanced Oncology	$150.0K	3	6.1%	1

VEF SAU imports 2 pharmaceutical products across 1 categories into Uzbekistan totaling $300.0K. The company is the #1 buyer for 1 product: Ifosfamide.

VEF SAU — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

VEF SAU is a pharmaceutical importer and buyer based in Tashkent, Uzbekistan. The company specializes in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily for the oncology therapeutic category. VEF SAU operates as a subsidiary enterprise, indicating a potential affiliation with a larger parent company, though specific details about its parent organization are not publicly disclosed. The company's role in Uzbekistan's pharmaceutical distribution network involves sourcing and importing essential medications to meet the country's healthcare needs, particularly in the oncology sector.

2Distribution Network

VEF SAU's distribution network is centered in Tashkent, the capital city of Uzbekistan. The company's primary warehouse is located at 15 Istikbol Street, Yashnabad District, Tashkent, Uzbekistan. This strategic location facilitates efficient logistics and distribution within the city and to other regions of Uzbekistan. While specific details about additional warehouse locations or logistics capabilities are not publicly available, the central position in Tashkent suggests a focus on domestic distribution. There is no publicly available information indicating that VEF SAU extends its distribution network beyond Uzbekistan.

3Industry Role

VEF SAU functions as a pharmaceutical importer and buyer within Uzbekistan's healthcare sector. The company's activities involve sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and importing them into Uzbekistan. VEF SAU's role is crucial in ensuring the availability of essential medications, especially in specialized therapeutic areas such as oncology. By importing these products, VEF SAU contributes to the diversification of the pharmaceutical supply chain in Uzbekistan, potentially reducing reliance on a single source and enhancing the resilience of the healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — VEF SAU

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

VEF SAU's sourcing strategy exhibits a high degree of concentration, with all its pharmaceutical imports originating from a single supplier: Vivalia Remedies Private Limited in India. This single-source dependency could pose risks, such as supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by the supplier. However, the consistent volume of shipments—six in total—suggests a stable and ongoing relationship between VEF SAU and Vivalia Remedies. The equal distribution of import value between the two products, Bleomycin and Ifosfamide, indicates a balanced demand for these medications within VEF SAU's portfolio. While the current supplier relationship appears stable, VEF SAU may consider diversifying its supplier base to mitigate potential risks associated with single-source dependency.

2Supply Chain Resilience

VEF SAU's supply chain resilience is closely tied to its exclusive reliance on Vivalia Remedies Private Limited for pharmaceutical imports. The absence of backup suppliers means that any disruption in Vivalia Remedies' operations could directly impact VEF SAU's ability to meet market demand. The limited diversity in imported formulations—two products across one therapeutic category—suggests a focused product strategy but also indicates vulnerability to supply chain disruptions. Additionally, the lack of publicly available information about shipping routes and the regulatory compliance status of Vivalia Remedies Private Limited makes it challenging to fully assess the robustness of the supply chain. To enhance resilience, VEF SAU might explore establishing relationships with alternative suppliers and expanding its product portfolio to include a broader range of therapeutic areas.

Importing Pharmaceuticals into Uzbekistan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Uzbekistan

1Regulatory Authority & Framework

In Uzbekistan, the pharmaceutical industry is regulated by the Ministry of Health, which oversees the registration, certification, and quality control of pharmaceutical products. The primary legislation governing pharmaceutical imports includes the Law on Medicines and Pharmaceutical Activities, which outlines the procedures for state registration, importation, and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining state registration from the Ministry of Health, which may include submitting documentation such as certificates of analysis, manufacturing licenses, and evidence of compliance with Good Manufacturing Practice (GMP) standards. The registration process is designed to ensure that imported pharmaceutical products meet the safety, efficacy, and quality standards required for the Uzbek market.

2Import Licensing & GMP

Import licensing in Uzbekistan requires that pharmaceutical products undergo state registration with the Ministry of Health. This process involves submitting comprehensive documentation, including certificates of analysis, manufacturing licenses, and evidence of compliance with GMP standards. Uzbekistan recognizes GMP certificates from countries and organizations that are members of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), as well as from the European Union and the World Health Organization (WHO). For Indian exporters, obtaining a GMP certificate from a recognized authority is essential to facilitate the importation of their products into Uzbekistan. Additionally, wholesale distribution authorization is required for companies involved in the import and distribution of pharmaceutical products within the country.

VEF SAU — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

VEF SAU's product strategy focuses exclusively on the oncology therapeutic category, importing two specific products: Bleomycin and Ifosfamide. This targeted approach suggests a strategic decision to concentrate on a specialized market segment, potentially to establish expertise and a strong market presence in oncology. The market demand for these products is likely driven by the prevalence of cancer in Uzbekistan and the need for effective treatments. By focusing on oncology, VEF SAU may aim to address critical healthcare needs and differentiate itself in the pharmaceutical import sector.

2Sourcing Profile

VEF SAU's sourcing strategy is centered on importing generic drugs from India, with a particular emphasis on oncology medications. The company's formulation preferences are limited to finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. India's established pharmaceutical manufacturing capabilities and competitive pricing make it an attractive source for these products. VEF SAU's procurement strategy appears to prioritize cost-effectiveness and reliability, leveraging India's strengths in generic drug production to meet the specific needs of the Uzbek market.

3Market Positioning

Seller's Guide — How to Become a Supplier to VEF SAU

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Uzbek market and collaborate with VEF SAU. The company's current sourcing pattern, characterized by a single-source dependency, indicates potential for diversification. Indian exporters can explore this opportunity by demonstrating the ability to meet VEF SAU's specific product requirements, quality standards, and regulatory compliance. Establishing a reliable supply chain and building trust with VEF SAU would be crucial steps for Indian exporters seeking to become alternative suppliers.

2Requirements & Qualifications

Indian exporters aiming to supply VEF SAU and the Uzbekistan market must obtain a GMP certificate from a recognized authority, such as the European Union, WHO, or PIC/S member countries. Additionally, they must ensure that their products meet

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — VEF SAU

What products does VEF SAU import from India?

VEF SAU imports 2 pharmaceutical products across 1 categories. Top imports: Bleomycin ($150.0K), Ifosfamide ($150.0K).

Who supplies pharmaceuticals to VEF SAU from India?

VEF SAU sources from 1 verified Indian suppliers. The primary supplier is Vivalia Remedies Private Limited (100.0% of imports, $300.0K).

What is VEF SAU's total pharmaceutical import value?

VEF SAU's total pharmaceutical import value from India is $300.0K, based on 6 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does VEF SAU focus on?

VEF SAU imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full VEF SAU Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Formulation	Value	Ships
Bleowel 15 units (bleomycin), 1x1	$150.0K	3
Fosfa + mesna (ifosfamide 1GM with	$150.0K	3